During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.